Dr. Eggener’s research and clinical interests focus on improving the management and outcomes for patients with localized prostate cancer with specific emphasis on active surveillance, focal therapy and optimizing surgical outcomes. He has published extensively on prostate cancer with 75 peer-reviewed publications and multiple on PSA screening, surgery, prostate imaging, active surveillance or focal therapy for prostate cancer. He is on the editorial board of four journals, including Prostate Cancer and Prostatic Diseases.
Memorial Sloan-Kettering Cancer Center
New York
Urologic oncology fellowship
Northwestern Memorial Hospital
Chicago
General and urologic surgery internship and residency
Standford University School of Medicine
California
MD
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline.
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. J Clin Oncol. 2025 Jan 09; JCO2402608.
PMID: 39787437
Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment.
Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment. Radiol Imaging Cancer. 2025 Jan; 7(1):e240156.
PMID: 39836080
Patterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node-Positive Prostate Cancer: A Multi-institutional Study.
Patterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node-Positive Prostate Cancer: A Multi-institutional Study. Pract Radiat Oncol. 2024 Dec 27.
PMID: 39733964
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour.
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour. BJU Int. 2024 Dec 11.
PMID: 39662898
Genomic Classifiers To Guide Postprostatectomy Radiation Therapy: An Opening Movement in G-MINOR.
Genomic Classifiers To Guide Postprostatectomy Radiation Therapy: An Opening Movement in G-MINOR. Eur Urol. 2024 Nov 29.
PMID: 39616001
Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling.
Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling. J Natl Cancer Inst. 2024 Nov 20.
PMID: 39565901
Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: A Worldwide Multicenter Study.
Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: A Worldwide Multicenter Study. Eur Urol Focus. 2024 Nov 16.
PMID: 39551650
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma.
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma. Clin Transl Radiat Oncol. 2024 Nov; 49:100879.
PMID: 39529961
Quantitative Multi-Parametric MRI of the Prostate Reveals Racial Differences.
Quantitative Multi-Parametric MRI of the Prostate Reveals Racial Differences. Cancers (Basel). 2024 Oct 16; 16(20).
PMID: 39456593
Prostate cancer and solid organ transplantation: patient management and outcomes.
Prostate cancer and solid organ transplantation: patient management and outcomes. BJU Int. 2025 Feb; 135(2):339-345.
PMID: 39385314